Know Cancer

or
forgot password

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer


N/A
18 Years
N/A
Not Enrolling
Female
Metastatic Breast Cancer

Thank you

Trial Information

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer


Inclusion Criteria:



- Patients that have received Abraxane chemotherapy greater than three months from the
time of chart review.

- Patients that have received taxane chemotherapy greater than three months from the
time of chart review.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Retrospective

Outcome Measure:

Describe patient demographics, disease and treatment characteristics.

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Jeffrey F Patton, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute

Authority:

United States: Institutional Review Board

Study ID:

SCRI OUTCOMES 02

NCT ID:

NCT00876070

Start Date:

November 2008

Completion Date:

February 2011

Related Keywords:

  • Metastatic Breast Cancer
  • Metastatic Breast Cancer
  • Breast Cancer
  • MBC
  • Abraxane
  • Paclitaxel
  • Taxol
  • Docetaxel
  • Taxotere
  • Breast Neoplasms

Name

Location

Georgia Cancer SpecialistsDecatur, Georgia  30033
Tennessee Oncology, PLLCClarksville, Tennessee  37043